At-home ketamine safety checklist

In the United States, the main legal at-home option is compounded oral or sublingual ketamine prescribed by a licensed clinician, usually through telehealth, where allowed by federal and state law. Remote integration therapy can also happen at home, but it is not dosing. Spravato, psilocybin, MDMA, LSD, ayahuasca, ibogaine, and 5-MeO-DMT are not legal take-home treatment options.

No. Spravato is available only through the Spravato REMS and must be administered under direct observation in a certified healthcare setting with monitoring for at least two hours. It must never be dispensed directly to a patient for home use.

No. FDA-approved ketamine is an injectable anesthetic, and Spravato is FDA-approved esketamine for certain depression indications under REMS. Compounded oral, sublingual, or nasal ketamine products are not FDA-approved for psychiatric disorders, and FDA has warned about risks when they are used at home without onsite monitoring.

A ketamine troche (sublingual lozenge) typically produces effects beginning within 10–20 minutes of dissolving under the tongue. The acute dissociative and mood-altering effects last approximately 45–75 minutes at standard therapeutic doses (100–300 mg). Residual sedation and mild disorientation can persist for 1–2 hours after the troche dissolves. Driving, operating machinery, or complex tasks should be avoided for at least 4 hours after dosing. Duration varies by dose, individual metabolism, and whether the lozenge is held sublingually (faster onset) or swallowed (slower onset, reduced effect).

At-home ketamine is a poor starting point for anyone in suicidal crisis, anyone with active psychosis or mania, uncontrolled blood pressure or major cardiac risk, pregnancy, significant substance-use risk, no sober support person, no safe setting, or no reliable follow-up with a clinician.

Generally no. At-home telehealth programs are structured as a self-pay monthly subscription, typically $129–$350/month, because they prescribe compounded oral or sublingual ketamine off-label rather than the FDA-approved Spravato (esketamine) nasal spray, which most commercial plans and Medicare Part B do cover with prior authorization. Spravato itself is not an at-home option — it must be administered in a certified healthcare setting under REMS. See our <a href="/guides/at-home-ketamine-therapy-cost">at-home ketamine cost guide</a> and <a href="/guides/ketamine-therapy-insurance-coverage">insurance coverage guide</a> for the full pricing and coverage breakdown.

Ketamine does not appear on standard 5-panel or 10-panel workplace drug tests. Those screens follow Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines covering marijuana, cocaine, amphetamines, opiates, and phencyclidine (PCP). Detection requires a specialized panel ordered for clinical, legal, or safety-sensitive settings, where urine tests identify ketamine for 3 to 6 days and norketamine for up to 11 days. Saliva tests detect use for roughly 24 to 48 hours, blood for about a day, and hair for 90 days, though metabolism, dose, and frequency affect these typical ranges.

Clinic-based intravenous (IV) infusions provide direct clinical monitoring and a standardized dose delivered by medical staff for the full session, whereas at-home ketamine is self-administered without onsite supervision. In-clinic care costs $400 to $800 per session, totaling $2,400 to $6,000 out of pocket for a standard 6-session induction course per the <a href="/guides/how-much-does-ketamine-therapy-cost">ketamine therapy cost guide</a>. At-home oral or sublingual troches run $129 to $350 per month, as documented in the <a href="/guides/at-home-ketamine-therapy-cost">at-home ketamine therapy cost guide</a>. The at-home option requires the patient, with a support person present, to manage their own environment and safety per the checklist on this page.